Survey Finds Majority of SAP Licensees Plan to Continue Running Their Proven ERP Release and Are Not Committed to Moving to S/4HANA
22.6.2017 21:05:00 EEST | Business Wire | Press release
Rimini Street, Inc., a global provider of enterprise software products and services, and the leading independent support provider for Oracle and SAP products, today revealed the findings from a recent global survey of SAP licensees conducted by Rimini Street to better understand their SAP application strategies and future plans. A key finding in the report is that the dominant strategy for SAP licensees, selected by 89% of respondents, is to continue running their current proven SAP ERP releases1, given that the rich functionality of their current releases meet business needs and also forms the foundation of a preferred hybrid IT model. Additionally, 65% of survey respondents have no plans to, or are currently not committed to, migrate to S/4HANA2, with the number one reason for not committing to S/4HANA cited as “no strong business case and unclear ROI.” The report, “Rimini Street Survey: 2017 SAP Applications Strategy Findings,” is based on responses from CIOs, CTOs, IT VPs, directors and managers from a broad range of industries and company sizes across North America, Europe, Latin America and Asia-Pacific.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170622006012/en/
Survey finds Majority of SAP Licensees Plan to Continue Running Their Proven ERP Release and Are Not Committed to Moving to S/4HANA (Photo: Business Wire)
Hybrid IT Strategy Optimizes the Value of SAP ERP
Of the survey respondents that plan to stay on their current SAP Business Suite application, 30% are already adopting a hybrid IT strategy to maximize the value of their core SAP system as a system of record, while also freeing up funds and resources that can be used to more quickly and flexibly drive innovation through systems of engagement. A hybrid IT strategy offers the best of both worlds – it provides the ability to reliably run the business on a robust core ERP application, and at the same time enables an organization to more quickly adopt new innovative applications and services, including cloud, mobile and analytics. Organizations have the flexibility to deploy systems of engagement from any technology provider, including SAP, which enables faster time to innovation and overall competitive advantage. In addition, an increasing number of companies are running their SAP ERP implementations in their private cloud or hosted environment, realizing many benefits of the cloud model without a costly, risky reimplementation. By shifting IT funds from expensive, disruptive upgrades to innovation, a hybrid strategy can accelerate the achievement of business objectives.
“When I speak with SAP customers, one of the most common strategies they enlist to maintain their core ERP while still having the ability to innovate, is to take a hybrid IT approach,” said Vinnie Mirchandani, CEO of Deal Architect and author of SAP Nation. “The SAP Business Suite is remarkably robust and feature rich, but SAP’s ability to successfully innovate outside core ERP has not kept up, so a two-speed approach makes sense. Stick with the proven core, but continue to innovate around the edges with many modern solutions that are available from some very nimble companies in the market today.”
High Cost and Risk of S/4HANA with Low ROI
In addition to citing “no strong business case and unclear ROI,” for the low commitment to S/4HANA, another top reason by survey participants for the low commitment to S/4HANA is the “high migration and reimplementation costs.” Of those respondents who have committed to S/4HANA, 56% estimated the total cost of reimplementation for a move to S/4HANA to be between $10 and $100 million, an expensive undertaking which makes it difficult to build a positive business case for the move and is financially untenable for many organizations.
Additional Survey Highlights:
-
47% of respondents consider SAP’s support and maintenance costs to
be too high
Nearly half of all respondents feel that SAP support and maintenance costs are too high, including those who state that the costs are “way out of control.” With the continued high cost of SAP support, budgets are squeezed and resources stretched thin. With Rimini Street, clients consistently realize cost savings of up to 90% in total maintenance costs as they are no longer on the upgrade path dictated by the vendor, no longer need to budget resource for self-support and no longer need to seek outside support for their customizations which are not covered by the vendor.
-
Respondents cite top issues with SAP’s support
The top three areas cited as problematic for SAP support, based on a survey question that allowed for multiple responses, include “Issues take too long to resolve” (36%), “Lack of support for customizations” (33%), and “Lack of expertise or adequate knowledge to resolve issues” (29%). These critical gaps in SAP support point to the need for an alternative solution that offers better, more responsive service than is available from the vendor today. Rimini Street addresses all of these issues by providing full support for SAP customizations, a dedicated Primary Support Engineer with an average of 15 years’ experience with SAP applications, and a guaranteed service level agreement response time of 15 minutes for critical issues.
“This survey highlights that CIOs and IT decision makers prefer to maximize the value of their current robust SAP ERP system that more than meets their business requirements, rather than advancing to a new platform that is still in development with no current business case to support a full reimplementation. It also illustrates how they are pursuing innovation strategies, such as hybrid IT, to help their business gain competitive advantage now, without having to wait indefinitely for meaningful new innovations and capabilities from SAP,” said Seth Ravin, Rimini Street CEO. “Today, Rimini Street supports nearly 1,300 clients running IBM, Microsoft, Oracle and SAP software, providing them with our premium-level enterprise software support and reducing their total maintenance costs by up to 90% – costs which can be redeployed to fund strategic initiatives for their business.”
To download a copy of the report “Rimini Street Survey: 2017 SAP Applications Strategy Findings,” please click here. For additional information on support services available to SAP licensees, please go here.
About Rimini Street, Inc.
Rimini Street is a global provider of enterprise software products and services, and the leading independent support provider for Oracle and SAP products. The company has redefined enterprise support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Nearly 1,300 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, independent support provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.
Forward-Looking Statements
This press release may contain forward-looking statements. The words “believe,” “may,” “will,” “plan,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and are based on various assumptions. If the risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Rimini Street assumes no obligation to update any forward-looking statements or information, which speak only as of the date of this press release.
© 2017 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
1, 2 Rimini Street Report, “Rimini Street Survey: 2017 SAP Applications Strategy Findings,” May 2017
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170622006012/en/
Contact information
Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
mmcglocklin@riministreet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
